Jan. 4, 2013
/PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Point-of-Delivery Drug Reconstitution Systems
Growth in the number of injectable drugs supplied in solid form for reconstitution prior to administration is being driven by the increase in drugs based on biological NCEs. These drugs are typically unstable at ambient temperatures and to preserve their shelf life must be either stored at low temperature (the so-call 'cold chain') or processed into a form that will preserve their pharmacological efficacy until they reach their therapeutic destination. Because the cost of transporting and storing drugs using refrigeration is expensive and requires constant temperature monitoring to insure that the drug has not been exposed to environmental conditions that render unsafe for use as a therapeutic product, technologies such as lyophilization are becoming more prevalent. The packaging and technologies developed and marketed for safe and reliable reconstitution at the point of administration are benefiting from this market trend. This report examines commercial drug reconstitution devices and systems and their impact on the injectable drug delivery sector.
- Analyzes therapeutic demand drivers and evaluates the market impact and potential of commercial drug reconstitution systems
- Provides analysis of injectable drugs for reconstitution and assesses key market segments, market dynamics and market demographics
- Forecasts Injectable drug product demand by indication and therapy to 2017
- Profiles reconstitution system suppliers, their product activities, business strategies, and corporate alliances and affiliations
Prolonging the Shelf Life of Biological Drugs
Lyophilization and Reconstitution at the Point of Use
Healthcare Economics and Reconstitution Systems
What's Driving the Growth in Engineered Reconstitution Systems?
Biological Drugs Proliferating
The Trend toward Self-Administration